Sulfosuccinimidyl oleate sodium (SSO sodium salt) is a long chain fatty acid acting as an irreversible inhibitor of the fatty acid translocase CD36, blocking uptake of oleate, linoleate, or stearate by about 65% when added at 200 µM to adipocytes.

BMS-8 is a novel small molecule inhibitor of the PD-1 (Programmed death-1)/PD-L1 (Programmed death-ligand 1) protein/protein interaction with potential anticancer activities.

(-)-JQ-1 is the (R)-Enantiomer of JQ1 or the stereoisomer of (+)-JQ1.

BMS-242 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 protein protein interaction with IC50 value in the range of 6-100 nM in cell free assays. It was first discovered by Bristol-Myers Squibb. Blockade of the PD-1/PD-L1 immune checkpoint pathway with monoclonal antibodies has provided significant advances in cancer treatment. The antibody-based immunotherapies […]

BMS-200 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 protein protein interaction with IC50 value of 80 nM in cell free assays. It was first discovered by Bristol-Myers Squibb. Blockade of the PD-1/PD-L1 immune checkpoint pathway with monoclonal antibodies has provided significant advances in cancer treatment. The antibody-based immunotherapies carry a number […]

BMS-1 (also known as PD1-PDL1-IN1, or PD1/PD-L1 inhibitor 1) is a novel and highly potent small molecule inhibitor of PD-1/PD-L1 protein/protein interaction with an IC50 of 6 nM.

AUNP-12 (also known as Aur-012, Aurigene-012, and Aurigene NP-12), a novel and potent immune checkpoint modulator developed by Aurigene Discovery Technologies, is an inhibitor of the PD-1 signalling pathway with an EC50 of 0.72 nM in the inhibition of binding PD1 to PD-L2 using hPDL2 expressing HEK293 cells, and an EC50 of 0.41 nM in […]

PD1-PDL1 inhibitor 2 (also known as BMS-202, BMS 202, BMS202), is a novel and potent inhibitor of the PD-1 (Programmed death- 1)/PD-Ll (Programmed death-ligand 1) protein/protein interaction with potential antineoplastic activity.

BMS-1233 (BMS1233) is novel and potent small molecule inhibitor of the PD-1/PD-L1 protein protein interaction with an IC50 of<100 nM in the HTRF assay.

BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 protein protein interaction with IC50 value of 1.6 nM in cell free assays.